Drug Profile
Research programme: adipose mesenchymal stem cell derived therapeutic factor concentrates - Theratome Bio/Cytovance Biologics
Alternative Names: NFx-101Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator NeuroFx
- Developer Cytovance Biologics; Theratome Bio
- Class Stem cell factors
- Mechanism of Action Angiogenesis inducing agents; Apoptosis inhibitors; Macrophage inhibitors; Neurogenesis stimulants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Brain injuries; Neurological disorders
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Brain injuries in USA (Parenteral)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Neurological-disorders in USA (Parenteral)
- 12 Aug 2015 Preclinical trials in Brain injuries in USA (Parenteral) prior to August 2015